• Proteomics R&D
• Proteomics Partnering
• Genomics R&D
• Recent Publications
• Pharmacogenomics Partnering
  • Clinical trial enrichment

Genomics Discovery for Diagnostics and Therapeutics

Case-control disease association studies with over 100,000 carefully selected consented specimens with clinical records Functional genome scans interrogate ~30,000 SNPs concentrated in genes and regulatory regions Advanced programs underway in cardiovascular and Alzheimer’s disease, autoimmunity, breast cancer metastasis, and liver disease Identified, replicated and filed patents on hundreds of novel markers and dozens of novel targets

Celera is unique in its ability to implement your pharmacogenomic strategy from the discovery of prognostic and predictive markers to the delivery of diagnostic tests.

Celera’s association study discovery platform allows high throughput genotyping and experimental flexibility.

Our genotyping services include the use of:

• Over 30,000 confirmed SNP assays, of which 75% are functional SNPs
• Custom assay design and development, and
• Sophisticated data management, bioinformatics, and statistical analysis

Celera is a leader in the development of in vitro diagnostic assays to guide physicians to the right treatment for each patient. We have an FDA-cleared genotype kit for mutations in the HIV-1 virus (ViroSeq^TM) HIV-1 Genotyping System that enables doctors to tailor their therapies for each individual to the type of HIV virus that is present. We offer analyte specific reagents (ASRs) produced in our GMP-compliant manufacturing facility to CLIA approved laboratories that may be used in the development of laboratory developed tests.

Let us use our knowledge of pharmacogenomics to advance your drug discovery program; together our focused efforts will set you on the critical path to new medical products.

Contact the Alliance Management Office for further information.

Alliance.Management@celera.com